Answers are grounded in this paper and cite their sources.
Secondary analysis assesses clozapine response in Black patients, highlighting treatment efficacy and demographic differences.
Objectives/Goals: Clozapine is the most effective treatment for people with treatment-resistant schizophrenia but is underutilized. Black patients are less likely to receive clozapine than White patients. Given limited data on the efficacy of clozapine in this population, we assessed clinical response in a large clinical trial of clozapine in Black patients. Methods/Study Population: This secondary analysis of a 6-month prospective, open-label clinical trial of clozapine in Black patients with schizophrenia spectrum disorders included 221 participants, 103 from Maryland, and 118 from Nigeria. The primary outcome was reduction in symptom severity as measured by total Brief Psychiatric Rating Scale (BPRS) over time on clozapine and modeled by a linear mixed effects model adjusted for age, sex, location, marital status, diagnosis, smoking status, Duffy null (ACKR-1 CC) genotype, clozapine dose, and clozapine level. We also assessed (i) changes in BPRS subscales over time, (ii) predictors of 20% improvement in BPRS, (iii) time to 20% BPRS improvement, and (v) the burden of clozapine side effects and the association of side effects and clinical improvement. Results/Anticipated Results: The average age was 40.2 years; 63% were male, 78% had schizophrenia, and 20% had schizoaffective disorder. BPRS total scores improved by 10.94 points (p < 0.001), adjusting for age, sex, and clozapine dose. Participants showed significant improvement in positive, resistance, affective, and activation, but not negative subscale scores. Nigerian participants were 21.5 times more likely to demonstrate 20% BPRS improvement compared to Maryland participants (p <0.001) and showed improvement more quickly, with most of the improvement in the first 4 weeks in Nigerian participants and 12 weeks for those in Maryland. 44.1% of participants had weight gain of at least 5% from baseline to endpoint. Improvement in tardive dyskinesia (p = 0.008) and weight gain (p < 0.001) were associated with BPRS improvement. Discussion/Significance of Impact: This study demonstrates clozapine’s efficacy in Black patients with schizophrenia spectrum disorders. Greater improvement in Nigerian participants may reflect differences in treatment resistance, social support, or expectation bias across groups. Further research is needed to improve utilization of clozapine in Black patients.
No takes yet. Share an insight, caveat, or question.
Brandt et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: